Eli Lilly eventually responded ... Flavier succinctly put it: "Dr Aguilar has contributed so much in the discovery of erythromycin. It is sad to hear that he got nothing out of it." ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more ...